BioVie Inc.: Business Overview, Financials & Competitive Analysis
BioVie Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage nanocap with multi-disease bezisterim potential, but pre-revenue, heavily cash-constrained, and dependent on near-term trial readouts. BioVie operates at nanocap scale with $11M-$17M market capitalization and zero revenue, yet holds multi-indication Phase 2 clinical data and DOD-backed funding for Long COVID research. Near-term value inflection depends entirely on trial readouts.
What is BioVie Inc.'s industry? BioVie Inc. (bioviepharma.com) operates in Biotechnology. AskCyborg classifies BioVie Inc. under Biotechnology in its company registry.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) a...
Cyborg Score thesis
Clinical-stage nanocap with multi-disease bezisterim potential, but pre-revenue, heavily cash-constrained, and dependent on...
Read the full analyst-debate transcript →Get the Latest BioVie Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBioVie Inc. Overview
Pro stress-test →BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson's disease and long COVID) and advanced liver disease. The company's pipeline is built around two core assets: bezisterim (NE3107) targeting neuroinflammation, and BIV201 for advanced liver disease management.
Strategic Profile
Pro stress-test →Its lead asset, bezisterim (NE3107), is a first-in-class, orally available small molecule that generated encouraging Phase 2 results in early Parkinson's disease, including statistically significant improvements across motor and non-motor measures, reductions in inflammatory biomarkers, and favorable changes in markers of neurodegeneration. The company plans to separate the BIV201 asset into Option Therapeutics, which is pursuing independent financing to advance BIV201 into Phase 3 while BioVie is expected to retain a majority ownership position.
Competitive Landscape
Pro stress-test →BioVie competes in clinical-stage neurodegeneration and advanced liver disease spaces against larger biotech companies with established pipelines and superior capital positions. Direct competitors include Eli Lilly, Biogen, and Roche in Alzheimer's/Parkinson's development, and Intercept Pharmaceuticals and Gilead Sciences in liver disease. BioVie's differentiation hinges on bezisterim's first-in-class TNF-α inhibition mechanism and multi-indication optionality, though execution risk is elevated given nanocap scale and pre-revenue status.
Industry Context
BioVie Inc. operates in Biotechnology.
Key facts
Founded: 2013 · Headquarters: Carson City, Nevada, US · Employees: 13 · Revenue: $0 as of Q1 2026 · Market cap: $11.0M-$17.3M